AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
Pre-Market: $197.33 -0.11 (-0.06%) 8:14 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
Pre-Market: $197.33 -0.11 (-0.06%) 8:14 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
The Extreme Risks of Trading Your Own Retirement Assets - March 25, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 24, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.
Roche Gets FDA Approval for Actemra Trials in COVID-19
by Zacks Equity Research
Roche (RHHBY) gets FDA nod to evaluate Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
Powerful Proof Anyone Can Invest for an Early Retirement - March 24, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Top Ranked Income Stocks to Buy for March 24th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 24th.
Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Macy's, AbbVie, Pfizer and New Residential Investment
4 Dividend Stocks to Buy Amid the Coronavirus Rout
by Nitish Marwah
The coronavirus has dealt a huge blow to markets globally. Valuations have gone for a toss across every asset class and sector.
AbbVie Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AbbVie has been struggling lately, but the selling pressure may be coming to an end soon.
Is AbbVie (ABBV) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
What Makes AbbVie (ABBV) a New Buy Stock
by Zacks Equity Research
AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Merck's Chronic Cough Candidate Achieves Goals in Phase III
by Zacks Equity Research
Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.
Johnson & Johnson (JNJ) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Johnson & Johnson (JNJ) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - March 18, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - March 18, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $72.99, marking a -1.72% move from the previous day.
How Trading Your Own Retirement Can Fleece Your Financial Future - March 17, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
AbbVie (ABBV) Jumps: Stock Rises 8.6%
by Zacks Equity Research
AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Simple Secrets Anyone Can Use to Reach Early Retirement - March 16, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
J&J Signs Another Collaboration to Develop Coronavirus Vaccine
by Zacks Equity Research
J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.
Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
by Kinjel Shah
Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.
Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
by Zacks Equity Research
Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.
Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA
by Zacks Equity Research
Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.